These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38551737)

  • 1. Differential tempol effects in prostatic cancer: angiogenesis and short- and long-term treatments.
    Santos FR; Rossetto IMU; Montico F; de Almeida Lamas C; Cagnon VHA
    J Mol Histol; 2024 Jun; 55(3):253-264. PubMed ID: 38551737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Montico F; Kido LA; Hetzl AC; Cagnon VH
    Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model: A good alternative to study PCa progression and chemoprevention approaches.
    Kido LA; de Almeida Lamas C; Maróstica MR; Cagnon VHA
    Life Sci; 2019 Jan; 217():141-147. PubMed ID: 30528182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tempol differential effect on prostate cancer inflammation: In vitro and in vivo evaluation.
    Rossetto I; Santos F; Kido L; Lamas C; Montico F; Cagnon V
    Prostate; 2023 Apr; 83(5):403-415. PubMed ID: 36546327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
    da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
    J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
    Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
    Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: contribution to the epithelial-stromal interaction balance.
    Nogueira Pangrazi E; da Silva RF; Kido LA; Montico F; Cagnon VHA
    Cell Biol Int; 2018 Feb; 42(2):153-168. PubMed ID: 28980742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.
    Montico F; Lamas CA; Rossetto IMU; Baseggio AM; Cagnon VHA
    J Mol Histol; 2023 Aug; 54(4):379-403. PubMed ID: 37335420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
    Huss WJ; Barrios RJ; Greenberg NM
    Mol Cancer Ther; 2003 Jul; 2(7):611-6. PubMed ID: 12883033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
    Kido LA; Montico F; Sauce R; Macedo AB; Minatel E; Costa DB; Carvalho JE; Pilli RA; Cagnon VH
    Endocr Relat Cancer; 2016 Apr; 23(4):235-50. PubMed ID: 26772819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis and prostate cancer: identification of a molecular progression switch.
    Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM
    Cancer Res; 2001 Mar; 61(6):2736-43. PubMed ID: 11289156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
    Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
    Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tempol, a Superoxide Dismutase-Mimetic Drug, Ameliorates Progression of Renal Disease in CKD Mice.
    Ding W; Wang B; Zhang M; Gu Y
    Cell Physiol Biochem; 2015; 36(6):2170-82. PubMed ID: 26279424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tempol effect on oxidative and mitochondrial markers in preclinical models for prostate cancer.
    Rossetto IMU; Santos FR; da Silva HM; Minatel E; Mesquitta M; Salvador MJ; Montico F; Cagnon VHA
    Toxicol Res (Camb); 2024 Apr; 13(2):tfae056. PubMed ID: 38623092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells.
    Lejeune D; Hasanuzzaman M; Pitcock A; Francis J; Sehgal I
    Mol Cancer; 2006 Jun; 5():21. PubMed ID: 16756681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
    Singh RP; Raina K; Sharma G; Agarwal R
    Clin Cancer Res; 2008 Dec; 14(23):7773-80. PubMed ID: 19047104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1
    Chiarotto GB; Cartarozzi LP; Perez M; Biscola NP; Spejo AB; Gubert F; França Junior M; Mendez-Otero R; de Oliveira ALR
    J Neuroinflammation; 2019 Nov; 16(1):218. PubMed ID: 31727149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
    Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
    Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies.
    Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM
    J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of omega-3 PUFAS on tumor progression at early and advanced stages in TRAMP mice.
    Amaro GM; da Silva ADT; Tamarindo GH; Lamas CA; Taboga SR; Cagnon VHA; Góes RM
    Prostate; 2022 Dec; 82(16):1491-1504. PubMed ID: 36039485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.